Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Università Degli Studi Di Milano manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution involves 1 distinct examiner, HUMPHRIES, NICHOLAS ADAM, and 1 distinct art unit. HUMPHRIES, NICHOLAS ADAM is the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending action. This indicates that the university's current patenting efforts are focused on a single innovation.
For the practitioner, having 1 distinct examiner means that the prosecution strategy can be tailored to the specific habits of HUMPHRIES, NICHOLAS ADAM. The 1 pending office action represents the entire active workload, allowing for a dedicated and efficient response. This 1 busiest examiner pending arrangement within 1 distinct art unit simplifies the management of the portfolio. The specific focus on the 1 distinct art unit suggests that the university is pursuing a specialized pharmaceutical technology through the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUMPHRIES, NICHOLAS ADAM | 1 | 34.2% | +76.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17778705 | MATERIALS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH THE IGHMBP2 GENE | HUMPHRIES, NICHOLAS ADAM | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17778705 | MATERIALS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH THE IGHMBP2 GENE | HUMPHRIES, NICHOLAS ADAM | 1631 | §103DP | Non-Final OA | — | Pending | May 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversità Degli Studi Di Milano has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nicholas Adam Humphries has the most, with 1 of Università Degli Studi Di Milano's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
